CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Letters of Credit Outstanding, Amount
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) had Letters of Credit Outstanding, Amount of $21.70 million as of 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Other Liabilities and Financial Instruments Subject to Mandatory Redemption
us-gaap:LettersOfCreditOutstandingAmount · last filed 2026-08-05
- 2026-06-27: Letters of Credit Outstanding, Amount $21.70M.
- 2026-03-28: Letters of Credit Outstanding, Amount $22.00M.
- 2025-12-27: Letters of Credit Outstanding, Amount $22.00M.
- 2024-12-28: Letters of Credit Outstanding, Amount $22.40M.
| Period end | Letters of Credit Outstanding, Amount |
|---|---|
| 2026-06-27 | $21.70M 10-Q · filed 2026-08-05 |
| 2026-03-28 | $22.00M 10-Q · filed 2026-05-07 |
| 2025-12-27 | $22.00M 10-Q · filed 2026-08-05 |
| 2024-12-28 | $22.40M 10-K · filed 2026-02-18 |
| 2023-12-30 | $21.60M 10-K · filed 2025-02-19 |
| 2015-09-26 | $4.90M 10-Q · filed 2015-11-04 |
| 2015-06-27 | $4.90M 10-Q · filed 2015-07-30 |
| 2015-03-28 | $5.00M 10-Q · filed 2015-04-30 |
| 2014-12-27 | $5.00M 10-Q · filed 2015-11-04 |
| 2014-09-27 | $5.01M 10-Q · filed 2014-10-30 |
| 2014-06-28 | $5.01M 10-Q · filed 2014-08-07 |
| 2014-03-29 | $5.11M 10-Q · filed 2014-04-30 |
| 2013-09-28 | $4.86M 10-Q · filed 2013-10-30 |
| 2013-06-29 | $4.86M 10-Q · filed 2013-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |